USANA Health Sciences (NYSE:USNA) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of USANA Health Sciences (NYSE:USNA) from a buy rating to a hold rating in a research note issued to investors on Saturday morning.

Several other brokerages have also recently commented on USNA. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research note on Wednesday, June 24th. Zacks Research lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 22nd. Two equities research analysts have rated the stock with a Sell rating, According to data from MarketBeat, USANA Health Sciences has a consensus rating of “Sell”.

USANA Health Sciences Trading Down 7.5%

Shares of NYSE:USNA opened at $14.31 on Friday. USANA Health Sciences has a 1 year low of $14.19 and a 1 year high of $32.32. The business has a fifty day simple moving average of $20.33 and a 200 day simple moving average of $19.59. The firm has a market cap of $264.16 million, a price-to-earnings ratio of -11.83, a P/E/G ratio of 1.70 and a beta of 0.73.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.50). USANA Health Sciences had a negative net margin of 2.43% and a positive return on equity of 3.41%. The firm had revenue of $223.27 million for the quarter, compared to analyst estimates of $235.00 million. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS. On average, sell-side analysts forecast that USANA Health Sciences will post 0.76 EPS for the current year.

Insiders Place Their Bets

In other news, CFO G Doug Iiekking sold 5,360 shares of the business’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $18.75, for a total value of $100,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Brent Neidig sold 5,002 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total transaction of $97,288.90. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 13,869 shares of company stock valued at $261,441 over the last quarter. Insiders own 0.82% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in USANA Health Sciences during the 2nd quarter valued at approximately $33,182,000. Pzena Investment Management LLC bought a new stake in shares of USANA Health Sciences in the second quarter valued at approximately $25,739,000. Renaissance Technologies LLC boosted its position in shares of USANA Health Sciences by 1.9% in the fourth quarter. Renaissance Technologies LLC now owns 1,147,323 shares of the company’s stock valued at $22,522,000 after acquiring an additional 21,793 shares during the period. Vanguard Group Inc. grew its stake in shares of USANA Health Sciences by 5.7% in the third quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock worth $29,452,000 after acquiring an additional 57,249 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of USANA Health Sciences by 1.9% in the third quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company’s stock worth $25,210,000 after acquiring an additional 17,318 shares during the last quarter. Institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah?based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight?management products and skin?care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical?grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.